Novartis shares fall as Entresto sales weaken
Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.
Newsletters and Deep Dive digital magazine
Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.
John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.
A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.
After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
Editor's Picks
Newsletters and Deep Dive
digital magazine